Ranjit Bindra, M.D., Ph.D.
Cybrexa Chief Scientific Advisor
Ranjit Bindra is a physician-scientist and biotech entrepreneur at the Yale School of Medicine. Clinically, he treats adult and pediatric primary CNS tumors, and he is a member of the Yale radiosurgery team, with expertise in treating brain metastases and benign tumors such as arteriovenous malformations. He also runs Phase I and II clinical trials testing experimental therapeutics at Yale, which are largely based on discoveries from his own laboratory. His group recently led a team of four major laboratories at Yale, which reported the stunning discovery that IDH1/2-mutant tumors harbor a profound DNA repair defect that renders them exquisitely sensitive to PARP inhibitors. This work was published in Science Translational Medicine, and has received international attention with major clinical implications.
As a biotech entrepreneur, Dr. Bindra has started two life sciences ventures over the last 10 years, and he is incubating a third company via a Program in Innovative Therapeutics for Connecticut’s Health (PITCH) award at Yale. The first company, Helix Therapeutics, was launched after winning the Yale Entrepreneurial Society (Y50K) business plan competition in 2006. The company reached a series B round of funding and was awarded several SBIR grants during its life cycle. More recently, he co-founded Cybrexa Therapeutics.
Dr. Bindra received his undergraduate degree in Molecular Biophysics and Biochemistry from Yale University, and both his MD and PhD from the Yale School of Medicine. He completed his medical internship, radiation oncology residency, and post-doctoral research studies at the Memorial Sloan-Kettering Cancer Center.
5 Science Park 395 Winchester Ave. New Haven, CT 06511 (860) 717-2731